Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several atorvastatin-specific safety statements align with provided label excerpts (e.g., skeletal muscle/myopathy, liver function monitoring). However, multiple claims involve torsemide (dehydration/electrolyte effects, torsemide-related interaction guidance, and specific symptom examples) for which no FDA label text was provided, and some patient-facing instructions cannot be verified against the supplied excerpts.
Category Scores
Accurate Statements
Atorvastatin can cause rare but serious muscle side effects such as muscle pain or weakness.
Supported by 5.1 Skeletal Muscle and 17.1 Muscle Pain in provided label excerpts.
A clinician may adjust doses if a patient is on other medicines or has certain health conditions.
Supported by 5.1 (consider lower starting/maintenance doses with interacting drugs; table-based recommendations) and 5.2 (dose reduction/withdrawal if ALT/AST >3x ULN persists).
Unsupported Statements
There isn’t a well-known, dangerous interaction between atorvastatin (Lipitor) and torsemide.
No FDA label excerpt provided for torsemide interactions, and absence of a specific interaction statement in the supplied excerpts cannot substantiate the claim.
Torsemide can cause dehydration.
No torsemide-specific FDA label text provided.
Torsemide can cause electrolyte changes.
No torsemide-specific FDA label text provided.
Dehydration or electrolyte imbalances can increase the risk of statin-related muscle side effects.
5.1 supports electrolyte disorders as risk factors in acute serious conditions, but the claim specifically frames 'dehydration' explicitly and is not directly supported as written by the provided excerpt.
Both atorvastatin and torsemide can affect liver and kidney function.
Atorvastatin liver enzyme abnormalities are supported (5.2) and renal failure secondary to rhabdomyolysis is mentioned (5.1), but no torsemide label text was provided.
A clinician may monitor blood tests for liver enzymes and kidney function when the drugs are used.
Provided excerpts clearly recommend liver function tests (5.2) and discuss closer monitoring for skeletal muscle effects (5.1), but do not clearly support routine 'kidney function' blood-test monitoring language for this combination within the supplied text.
Unexplained muscle pain, weakness, or dark urine are symptoms to report.
Label excerpt supports reporting unexplained muscle pain/tenderness/weakness (5.1), but 'dark urine' is not shown in the provided excerpts.
Jaundice (yellowing of the skin or eyes) is a symptom to report.
5.2 discusses a case of jaundice, but the provided excerpt does not explicitly instruct patients to report jaundice.
Severe dehydration, dizziness, or fainting are symptoms to report.
No provided label excerpt supports these specific symptom-reporting instructions.
Signs of electrolyte imbalance include confusion, numbness, or an irregular heartbeat.
No provided label excerpt supports these specific examples.
It is not advised to take Lipitor (atorvastatin) and torsemide together without medical supervision.
No torsemide-specific interaction/combination guidance was provided in the supplied label excerpts; only general interaction risk language for certain atorvastatin interacting agents is present.
You should not start or keep taking both drugs together without a doctor’s approval.
No explicit label support was provided for this patient-facing combination instruction in the supplied excerpts.
You should not change the doses on your own if you are already taking both drugs.
Provided excerpts include monitoring/discontinuation recommendations for specific clinical situations but do not explicitly support this specific patient instruction regarding dose changes 'if already taking both drugs'.
Contradictions
Important Omissions
Specific FDA label guidance on atorvastatin dosing/limits and prescribing recommendations for the particular interacting agent(s) involved with torsemide (if any), including whether torsemide appears in the provided label interaction tables.
Importance:
Moderate
Any boxed warning, contraindications, or full warnings/precautions text relevant to combination use; these sections were not provided in the supplied excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims about torsemide effects (dehydration/electrolyte changes) and torsemide-specific combination caution cannot be verified against the provided FDA label excerpts, reducing audit confidence for safety-related statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Torsemide-related claims and specific patient-facing symptom/combination instructions are not supported by the supplied FDA label excerpts.
Suggested Improvement
Limit statements to label-supported atorvastatin counseling and monitoring excerpts provided (e.g., report unexplained muscle pain/tenderness/weakness; liver function test timing). Remove or revise torsemide-specific claims unless torsemide label text and the relevant FDA drug interaction guidance are provided.